Anti-mesothelin mAbs react with renal cell carcinomas and pancreatic and ovarian cancers [28–30], unlike the JMAM4 mAbs that did not react with lung, ovarian, or renal cell carcinomas or any of the other cancer cell lines tested. This evidence concerns the gene MSLN and renal cell carcinoma.